Subscribe

Amexdrug Corporation (AXRX)

USD0.00 +0.00 (+0.00%)
US OTC Healthcare Drug Manufacturers - Specialty & Generic
Address 7251 Condor Street 90040
Commerce, CA, US
CEO Jack Amin
IPO 2001-03-29
ISIN US0311392072

Explore sections of this company profile

Description

Amexdrug Corporation, founded in 1963 and headquartered in Commerce, California, operates as a pharmaceutical and cosmeceutical enterprise. Primarily, the company, via its subsidiaries, distributes pharmaceutical products. Beyond this core function, Amexdrug is also deeply involved in the entire lifecycle of pharmaceutical drugs, cosmetics, and medical devices, from their research and development phases through manufacturing and ultimate sale. The company's operations are divided into two main divisions: Distribution and Health and Beauty Products. Its extensive distribution network encompasses a wide range of items, including prescription and over-the-counter medications, various non-drug products, and health and beauty essentials. Amexdrug also provides services in private manufacturing and labeling. Specific product lines manufactured and sold by the company, often under its Sponix brand, include facial and body creams, arthritic pain relief treatments, and hair and nail care products. These goods are supplied to a diverse clientele such as pharmacies, beauty salons, beauty supply outlets, and other retail establishments. Within the state of California, Amexdrug's distribution channels primarily target independent pharmacies, extending secondarily to smaller pharmacy chains, alternative care facilities, and various wholesalers and retailers. The company adopted the name Amexdrug Corporation in April 2000, changing from its previous identity as Harlyn Products, Inc., to reflect its strategic focus on pharmaceutical sales.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
USD0.00 +0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
68
Beta
-0.57
Float Shares
5.80M
Free Float %
3.4%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.00% +0.00% +0.00% +0.00% +0.00% +0.00% -90.00% -92.00% -99.82% -99.71% -99.80%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
0.00
DCF (Unlevered) 0.00 +556.8%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM)
Rating 2024-11 Change
Strong Buy 0 0
Buy 0 0
Hold 0 0
Sell 0 0
Strong Sell 0 0
Quality scores
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
  • Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    -14.6% Q1'26: -8.4% (vs Q4'24)
  • EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +100.0% Q1'26: +150.0% (vs Q4'24)
  • FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +1.4% Q1'26: +0.0% (vs Q4'24)
  • EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +4.7% Q1'26: +6.4% (vs Q4'24)
  • ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +25.7% Q1'26: +33.1% (vs Q4'24)
  • Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    +0.0% Q1'26: +0.0% (vs Q4'24)
  • Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    3.15× Q1'26: 2.23× (vs Q4'24)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
WACC components (optional)
Ke (Cost of Equity) = Rf + β (-0.52) × ERP
WACC = 7% × Ke + 93% × Kd (22.4%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
Intrinsic value (base): 0.00 Current price: 0.00
Enterprise Value: Equity Value: Terminal Value: TV as % of EV:

Base values reflect the latest available data for this company and market conditions.

Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-12 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
2026-05-05 C 2/5 1/5 1/5 1/5 2/5 1/5 5/5
Ownership data is not available for this company yet.

Executive team

Top executives
EBIT / Employee
15.2K
Shares Outstanding
169.41M

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Jack Amin Chairman, Chief Executive Officer, President, Chief Financial Officer, Chief Accounting Officer, Secretary & Treasurer 154.8K male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend history

Earnings reports

Stock splits